688428 诺诚健华
已收盘 10-27 15:00:00
资讯
新帖
简况
股市必读：诺诚健华三季报 - 第三季度单季净利润同比增长1292.60%
证券之星 · 03:55
股市必读：诺诚健华三季报 - 第三季度单季净利润同比增长1292.60%
诺诚健华：10月27日召开业绩说明会，投资者参与
证券之星 · 10-27 20:01
诺诚健华：10月27日召开业绩说明会，投资者参与
诺诚健华：截止到2026年9月30日公司A股股东户数约为2.1万户
证券之星 · 10-27 17:54
诺诚健华：截止到2026年9月30日公司A股股东户数约为2.1万户
诺诚健华：公司应收账款与药品销售收入相匹配
证券之星 · 10-27 17:54
诺诚健华：公司应收账款与药品销售收入相匹配
“止血”扭亏为盈后，诺诚健华的“造血”硬仗才刚开打
东方财富网 · 10-27 16:52
“止血”扭亏为盈后，诺诚健华的“造血”硬仗才刚开打
诺诚健华：第三季度营收达9.62亿元 同比上升150.6%
财中社 · 10-26 17:14
诺诚健华：第三季度营收达9.62亿元 同比上升150.6%
诺诚健华(09969)前三季度归母净利润约6.56亿元 同比扭亏为盈
智通财经 · 10-26 16:55
诺诚健华(09969)前三季度归母净利润约6.56亿元 同比扭亏为盈
【券商聚焦】国泰海通维持诺诚健华（09969）增持评级 指奥布替尼持续放量
金吾财讯 · 10-23
【券商聚焦】国泰海通维持诺诚健华（09969）增持评级 指奥布替尼持续放量
股市必读：诺诚健华新发布《诺诚健华医药有限公司关于召开2026年第三季度业绩说明会的公告》
证券之星 · 10-21
股市必读：诺诚健华新发布《诺诚健华医药有限公司关于召开2026年第三季度业绩说明会的公告》
诺诚健华（688428）披露召开2026年第三季度业绩说明会公告，10月19日股价上涨1.08%
证券之星 · 10-19
诺诚健华（688428）披露召开2026年第三季度业绩说明会公告，10月19日股价上涨1.08%
股市必读：诺诚健华新发布《港股公告：董事会召开日期》
证券之星 · 10-14
股市必读：诺诚健华新发布《港股公告：董事会召开日期》
股市必读：诺诚健华新发布《港股公告：董事会召开日期》
证券之星 · 10-13
股市必读：诺诚健华新发布《港股公告：董事会召开日期》
财报扭亏、重磅合作落地 诺诚健华创始家族为何轮番减持？
新浪证券 · 10-10
财报扭亏、重磅合作落地 诺诚健华创始家族为何轮番减持？
诺诚健华（688428）10月8日主力资金净买入6125.32万元
证券之星 · 10-09
诺诚健华（688428）10月8日主力资金净买入6125.32万元
10月8日诺诚健华跌7.15%，富国精准医疗混合A基金重仓该股
证券之星 · 10-08
10月8日诺诚健华跌7.15%，富国精准医疗混合A基金重仓该股
股市必读：诺诚健华新发布《诺诚健华医药有限公司关于持股5%以上股东权益变动触及1%刻度的提示性公告》
证券之星 · 10-08
股市必读：诺诚健华新发布《诺诚健华医药有限公司关于持股5%以上股东权益变动触及1%刻度的提示性公告》
诺诚健华盘中涨超5% 近日与礼来签署研发合作及授权许可协议
新浪港股 · 09-29
诺诚健华盘中涨超5% 近日与礼来签署研发合作及授权许可协议
瑞银：诺诚健华维持“买入”评级 目标价21.80港元
新浪港股 · 09-27
瑞银：诺诚健华维持“买入”评级 目标价21.80港元
瑞银：诺诚健华(09969)与礼来(LLY.US)就创新靶点项目达成合作 看法正面
智通财经 · 09-25
瑞银：诺诚健华(09969)与礼来(LLY.US)就创新靶点项目达成合作 看法正面
潜在总额33.5亿美元，股价跌幅超10% 诺诚健华牵手礼来后股价“过山车”
每日经济新闻 · 09-24
潜在总额33.5亿美元，股价跌幅超10% 诺诚健华牵手礼来后股价“过山车”
暂无数据
公司概况
公司名称：
诺诚健华医药有限公司
所属行业：
医药制造业
上市日期：
2022-09-21
主营业务：
诺诚健华医药有限公司的主营业务是创新药的研发、生产及商业化。公司的主要产品是奥布替尼、坦昔妥单抗及mesutoclax。
发行价格：
11.03
{"stockData":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":25.16,"timestamp":1793084400000,"preClose":25.74,"halted":0,"volume":12819719,"delay":0,"changeRate":-0.0225,"floatShares":273000000,"shares":1770000000,"eps":0.77,"marketStatus":"已收盘","change":-0.58,"latestTime":"10-27 15:00:00","open":27.31,"high":27.31,"low":25.16,"amount":331000000,"amplitude":0.0835,"askPrice":25.16,"askSize":35,"bidPrice":25.15,"bidSize":182,"shortable":0,"etf":0,"ttmEps":0.77,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793151000000},"marketStatusCode":5,"adr":0,"adjPreClose":25.74,"symbolType":"stock_kcb","openAndCloseTimeList":[[1793064600000,1793071800000],[1793077200000,1793084400000]],"highLimit":28.31,"lowLimit":23.17,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1769688139,"isCdr":false,"pbRate":5.43,"roa":"--","peRate":32.675325,"roe":"8.25%","epsLYR":0.38,"committee":0.168317,"marketValue":44525000000,"turnoverRate":0.0469,"status":1,"afterMarket":{"amount":0,"volume":0,"close":25.16,"buyVolume":7514,"sellVolume":0,"time":1793086437746,"indexStatus":"已收盘 10-27 15:30:00","preClose":25.74},"hkstockBrief":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"诺诚健华","latestPrice":11.42,"timestamp":1793088501012,"preClose":11.61,"halted":0,"volume":8289550,"delay":0,"premium":"-61.44"},"floatMarketCap":6879000000},"requestUrl":"/m/hq/s/688428/tweets","defaultTab":"tweets","newsList":[{"id":"2678883204","title":"股市必读：诺诚健华三季报 - 第三季度单季净利润同比增长1292.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678883204","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678883204?lang=zh_cn&edition=full","pubTime":"2026-10-28 03:55","pubTimestamp":1793130909,"startTime":"0","endTime":"0","summary":"截至2026年10月27日收盘，诺诚健华报收于25.16元，下跌2.25%，换手率4.69%，成交量12.82万手，成交额3.31亿元。业绩披露要点：2026年前三季度归母净利润6.56亿元，同比上升1117.93%；第三季度单季度归母净利润4.09亿元，同比上升1292.6%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800004018.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678917232","title":"诺诚健华：10月27日召开业绩说明会，投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2678917232","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678917232?lang=zh_cn&edition=full","pubTime":"2026-10-27 20:01","pubTimestamp":1793102475,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年10月27日诺诚健华发布公告称公司于2026年10月27日召开业绩说明会。相关对外引进事项尚存在不确定性，请投资者注意投资风险。根据公司季度报告，2026年第三季度公司营业收入9.62亿元，其中药品销售收入5.31亿元，其余营业收入主要为公司与Zenas达成的独家许可协议所实现的里程碑收入。公司与 Zenas 的合作项目正按协议计划稳步推进，2026年第四季度及2027年，协议项下存在若干临床开发节点具备里程碑触发的潜在可能性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700038250.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","09969","BK1161","BK0239","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678352120","title":"诺诚健华：截止到2026年9月30日公司A股股东户数约为2.1万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2678352120","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678352120?lang=zh_cn&edition=full","pubTime":"2026-10-27 17:54","pubTimestamp":1793094858,"startTime":"0","endTime":"0","summary":"证券之星消息，诺诚健华(688428)10月27日在投资者关系平台上答复投资者关心的问题。投资者提问：您好！请问截至9月底公司股东人数是多少，谢谢！诺诚健华回复：尊敬的投资者，您好！截止到2026年9月30日公司A股股东户数约为2.1万户。感谢您的关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700033154.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["82822","82823","BK0239","02822","03130","82843","BK1147","02827","02823","159982","82846","BK1610","83188","688428","02843","BK1161","83130","09969","03188","399300","BK1574","07233","02846"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678120866","title":"诺诚健华：公司应收账款与药品销售收入相匹配","url":"https://stock-news.laohu8.com/highlight/detail?id=2678120866","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678120866?lang=zh_cn&edition=full","pubTime":"2026-10-27 17:54","pubTimestamp":1793094848,"startTime":"0","endTime":"0","summary":"证券之星消息，诺诚健华(688428)10月27日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，首先祝贺下公司取得不错的业绩，但是我们也看到公司的应收账款远低于药品销售收入，造成这些的原因是哪些？如何改善？诺诚健华回复：尊敬的投资者，您好！公司应收账款与药品销售收入相匹配，公司应收账款结构良好，坏账风险低，回款周期正常。感谢您的关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700033146.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","688428","BK1574","BK1161","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678245801","title":"“止血”扭亏为盈后，诺诚健华的“造血”硬仗才刚开打","url":"https://stock-news.laohu8.com/highlight/detail?id=2678245801","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678245801?lang=zh_cn&edition=full","pubTime":"2026-10-27 16:52","pubTimestamp":1793091168,"startTime":"0","endTime":"0","summary":"蓝鲸新闻10月27日讯（记者何天骄）2026年三季报，诺诚健华（688428.SH/09969.HK）交出一份“扭亏+翻倍增长”的答卷：前三季度营收20.99亿元，同比增长88.21%；药品销售14.49亿元，同比增长41.47%；净利润6.48亿元，去年同期为亏损0.72亿元；达到2.2亿元，同比由负转正。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://finance.eastmoney.com/news/1354,202610273909931718.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/news/1354,202610273909931718.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["BK1161","688428","09969","BK1574","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678516669","title":"诺诚健华：第三季度营收达9.62亿元 同比上升150.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678516669","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678516669?lang=zh_cn&edition=full","pubTime":"2026-10-26 17:14","pubTimestamp":1793006041,"startTime":"0","endTime":"0","summary":"10月26日，诺诚健华(688428)公布2026年三季报，公司营业收入为20.99亿元，同比上升88.2%；归母净利润6.56亿元；扣非归母净利润5.86亿元；经营现金流净额为2.2亿元；EPS(全面摊薄)为0.39元。其中第三季度，公司营业收入为9.62亿元，同比上升150.6%；归母净利润4.09亿元；扣非归母净利润3.99亿元；EPS为0.24元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610263908097321.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610263908097321.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09969","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678163080","title":"诺诚健华(09969)前三季度归母净利润约6.56亿元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2678163080","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678163080?lang=zh_cn&edition=full","pubTime":"2026-10-26 16:55","pubTimestamp":1793004907,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华(09969)公布2026年前三季度业绩，公司总营业收入为 20.99 亿元，比上年同期增长 88.21%，其中药品销售收入为 14.49 亿元，比上年同期增长 41.47%。营业收入增长主要原因为核心产品奥布替尼持续放量、坦昔妥单抗和佐来曲替尼新增销售贡献以及公司与 Zenas BioPharma,Inc.的授权许可协议完成后续里程碑交付。归属于上市公司股东的净利润约6.56亿元，同比扭亏为盈。2026 年 1-9 月，公司经营活动产生的现金流量净额为 2.20 亿元，同比实现由负转正，主要得益于药品销售与授权许可收入增加，公司经营现金流状况持续改善。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1512430.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688428","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677594351","title":"【券商聚焦】国泰海通维持诺诚健华（09969）增持评级 指奥布替尼持续放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2677594351","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677594351?lang=zh_cn&edition=full","pubTime":"2026-10-23 14:21","pubTimestamp":1792736485,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国泰海通发布研报指，维持诺诚健华 “增持”评级，目标价19.31港元。核心逻辑为血液瘤产品销售良好、奥布替尼持续放量，自免管线迎来密集数据读出。诺诚健华与礼来达成研发和授权许可战略合作。根据协议条款，诺诚健华有权获得最高1亿美元的首付款和近期付款，以及最高32.5亿美元的开发和商业化里程碑付款；并有权就许可产品年度净销售额收取个位数百分比的分级特许权使用费。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994298","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02611","688428","KCE","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677618765","title":"股市必读：诺诚健华新发布《诺诚健华医药有限公司关于召开2026年第三季度业绩说明会的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2677618765","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677618765?lang=zh_cn&edition=full","pubTime":"2026-10-21 01:49","pubTimestamp":1792518551,"startTime":"0","endTime":"0","summary":"截至2026年10月20日收盘，诺诚健华报收于26.72元，上涨1.64%，换手率3.4%，成交量9.31万手，成交额2.46亿元。公司公告汇总诺诚健华医药有限公司关于召开2026年第三季度业绩说明会的公告诺诚健华医药有限公司将于2026年10月27日上午11:00-12:00通过上证路演中心网络互动方式召开2026年第三季度业绩说明会，介绍公司当季经营成果及财务状况。投资者可于2026年10月20日至10月26日16:00前通过上证路演中心网站或公司邮箱IR@innocarepharma.com提问。会后可通过上证路演中心查看会议情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102100001613.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","BK1161","09939","159938","BK1574","BK1515","BK0239","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676690684","title":"诺诚健华（688428）披露召开2026年第三季度业绩说明会公告，10月19日股价上涨1.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2676690684","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676690684?lang=zh_cn&edition=full","pubTime":"2026-10-19 22:33","pubTimestamp":1792420400,"startTime":"0","endTime":"0","summary":"截至2026年10月19日收盘，诺诚健华报收于26.29元，较前一交易日上涨1.08%，最新总市值为465.25亿元。该股当日开盘25.81元，最高27.2元，最低25.71元，成交额达2.75亿元，换手率为3.8%。公告显示，公司将于2026年10月27日上午11:00-12:00通过上证路演中心网络互动方式召开2026年第三季度业绩说明会，介绍公司当季经营成果及财务状况。投资者可于2026年10月20日至10月26日16:00前通过上证路演中心网站或公司邮箱IR@innocarepharma.com提问。会后可通过上证路演中心查看会议情况。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900030181.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","09969","BK1574","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675361897","title":"股市必读：诺诚健华新发布《港股公告：董事会召开日期》","url":"https://stock-news.laohu8.com/highlight/detail?id=2675361897","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675361897?lang=zh_cn&edition=full","pubTime":"2026-10-14 02:03","pubTimestamp":1791914590,"startTime":"0","endTime":"0","summary":"截至2026年10月13日收盘，诺诚健华报收于26.37元，下跌2.15%，换手率3.13%，成交量8.55万手，成交额2.25亿元。当日关注点交易信息汇总：10月13日主力资金净流入660.78万元，游资资金净流入2261.25万元，散户资金净流出2922.02万元。公司公告汇总：诺诚健华董事会将于2026年10月26日召开会议，审议截至2026年9月30日止九个月的第三季度未经审计业绩。董事会成员包括崔霁松博士、赵仁滨博士、施一公博士、谢榕刚先生、胡兰女士、董丹丹博士及管坤良教授。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400001707.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","BK1574","BK1161","BK0239","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675804961","title":"股市必读：诺诚健华新发布《港股公告：董事会召开日期》","url":"https://stock-news.laohu8.com/highlight/detail?id=2675804961","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675804961?lang=zh_cn&edition=full","pubTime":"2026-10-13 01:47","pubTimestamp":1791827233,"startTime":"0","endTime":"0","summary":"截至2026年10月12日收盘，诺诚健华报收于26.95元，下跌4.16%，换手率2.98%，成交量8.16万手，成交额2.24亿元。当日关注点交易信息汇总：10月12日主力资金净流入548.7万元，占总成交额2.45%。公司公告汇总：诺诚健华董事会将于2026年10月26日召开会议，审议截至2026年9月30日止九个月的第三季度未经审计业绩。董事会成员包括崔霁松博士、赵仁滨博士、施一公博士、谢榕刚先生、胡兰女士、董丹丹博士及管坤良教授。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101300001830.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","09969","BK1161","BK1574","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674896607","title":"财报扭亏、重磅合作落地 诺诚健华创始家族为何轮番减持？","url":"https://stock-news.laohu8.com/highlight/detail?id=2674896607","media":"新浪证券","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674896607?lang=zh_cn&edition=full","pubTime":"2026-10-10 14:36","pubTimestamp":1791614160,"startTime":"0","endTime":"0","summary":"然而，靓丽财报的另一面，是公司两大创始人家族轮番减持。9月24日，公司宣布与礼来达成总潜在金额33.5亿美元的重磅研发合作仅6天后，崔霁松家族即通过港股减持500万股。财报扭亏、重磅合作落地双创始家族为何轮番套现诺诚健华由崔霁松与施一公于2015年联合创立，成立之初便形成了清晰的双家族持股架构。施一公家族的减持最早启动于2026年二季度。第二轮减持则发生在重磅合作公布之后。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-10-10/doc-iniutkci6118384.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688428","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674378889","title":"诺诚健华（688428）10月8日主力资金净买入6125.32万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674378889","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674378889?lang=zh_cn&edition=full","pubTime":"2026-10-09 08:28","pubTimestamp":1791505737,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月8日收盘，诺诚健华报收于27.03元，下跌7.15%，换手率8.69%，成交量23.75万手，成交额6.49亿元。近5日资金流向一览见下表：诺诚健华融资融券信息显示，融资方面，当日融资买入4239.44万元，融资偿还4794.74万元，融资净偿还555.3万元。诺诚健华主营业务：主要从事生物医药研发、生产和商业化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900006145.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0239","BK1161","688428","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673027651","title":"10月8日诺诚健华跌7.15%，富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2673027651","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673027651?lang=zh_cn&edition=full","pubTime":"2026-10-08 16:40","pubTimestamp":1791448844,"startTime":"0","endTime":"0","summary":"证券之星消息，10月8日诺诚健华跌7.15%，收盘报27.03元，换手率8.69%，成交量23.75万手，成交额6.49亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共35家，其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为28.98亿元，最新净值3.2487，较上一交易日上涨2.6%，近一年下跌8.34%。富国精准医疗混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800021330.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1574","09969","688428","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673017467","title":"股市必读：诺诚健华新发布《诺诚健华医药有限公司关于持股5%以上股东权益变动触及1%刻度的提示性公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2673017467","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673017467?lang=zh_cn&edition=full","pubTime":"2026-10-08 03:19","pubTimestamp":1791400748,"startTime":"0","endTime":"0","summary":"公司公告汇总诺诚健华医药有限公司关于持股5%以上股东权益变动触及1%刻度的提示性公告诺诚健华医药有限公司持股5%以上股东Sunland BioMed Ltd及其一致行动人Stanley Holdings Limited、The Jisong Cui 2019 Irrevocable Trust、Jisong Cui（崔霁松）及直系亲属合计持股比例由7.23%减少至6.94%，持股数量由12,786.4032万股减少至12,286.4032万股。本次权益变动因Jisong Cui（崔霁松）个人资金需求所致，不触及要约收购，未违反承诺，不影响公司控制权及治理结构。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800001585.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1515","688428","BK1574","09939","BK0239","159938","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671262791","title":"诺诚健华盘中涨超5% 近日与礼来签署研发合作及授权许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2671262791","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671262791?lang=zh_cn&edition=full","pubTime":"2026-09-29 10:50","pubTimestamp":1790650200,"startTime":"0","endTime":"0","summary":"模拟交易客户端诺诚健华盘中涨超5%。诺诚健华近日宣布与礼来签署研发合作及授权许可协议，诺诚健华与礼来双方将在创新药物研发领域开展战略合作，诺诚健华将依托专有药物发现平台及深厚的研究经验，发现并开发至多5项创新性靶点项目，以解决重大未满足的临床需求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-29/doc-initnfqh2546504.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688428","BK1161","09969","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670410470","title":"瑞银：诺诚健华维持“买入”评级 目标价21.80港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670410470","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670410470?lang=zh_cn&edition=full","pubTime":"2026-09-27 12:28","pubTimestamp":1790483280,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端瑞银发布研报称，维持诺诚健华（09969）“买入”评级及目标价21.8港元。诺诚健华与礼来（LLY.US）就发现及开发最多5个创新靶点项目达成合作，该行对此持正面看法，认为属于对公司研发能力的认可。该行指出，预付款及近期里程碑付款合计1亿美元，潜在研发及商业里程碑付款达32.5亿美元，并可获得净销售额单位数百分比分层权利金。据管理层表示，所有项目均由药物发现阶段开始。相关付款或为2026年收入及净利润带来上行空间。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2026-09-27/doc-initftkn0360074.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09969","EWH","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670449487","title":"瑞银：诺诚健华(09969)与礼来(LLY.US)就创新靶点项目达成合作 看法正面","url":"https://stock-news.laohu8.com/highlight/detail?id=2670449487","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670449487?lang=zh_cn&edition=full","pubTime":"2026-09-25 17:06","pubTimestamp":1790327211,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞银发布研报称，维持诺诚健华(09969)“买入”评级及目标价21.8港元。诺诚健华与礼来(LLY.US)就发现及开发最多5个创新靶点项目达成合作，该行对此持正面看法，认为属于对公司研发能力的认可。该行指出，预付款及近期里程碑付款合计1亿美元，潜在研发及商业里程碑付款达32.5亿美元，并可获得净销售额单位数百分比分层权利金。据管理层表示，所有项目均由药物发现阶段开始。相关付款或为2026年收入及净利润带来上行空间。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688428","09969","BK0239","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669449587","title":"潜在总额33.5亿美元，股价跌幅超10% 诺诚健华牵手礼来后股价“过山车”","url":"https://stock-news.laohu8.com/highlight/detail?id=2669449587","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669449587?lang=zh_cn&edition=full","pubTime":"2026-09-24 21:17","pubTimestamp":1790255851,"startTime":"0","endTime":"0","summary":"9月24日，诺诚健华（SH688428）A股收盘价29.86元/股，日跌幅10.60%。消息面上，公司当日中午宣布与礼来公司达成战略研究合作及许可协议，下午开盘后先直线拉升，股价创出历史新高，达到35元/股。之后，股价又快速回落。根据公告，诺诚健华与礼来的交易总金额可观，最高可达33.5亿美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609243883899191.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609243883899191.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688428","BK1574","BK1161","BK0239","09969"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793135999962,"stockEarnings":[{"period":"1week","weight":-0.0584},{"period":"1month","weight":-0.1574},{"period":"3month","weight":-0.0828},{"period":"6month","weight":-0.0559},{"period":"1year","weight":0.0925},{"period":"ytd","weight":0.2261}],"compareEarnings":[{"period":"1week","weight":-0.0233},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.0471},{"period":"6month","weight":-0.1128},{"period":"1year","weight":-0.0872},{"period":"ytd","weight":-0.0808}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"诺诚健华医药有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"0人","perCapita":"--","listingDate":"2022-09-21","address":"Ogier Global (Cayman) Limited, 89 Nexus Way, Camana Bay, Grand Cayman, KY1-9009, Cayman Islands","registeredCapital":"0万元","survey":" 诺诚健华医药有限公司的主营业务是创新药的研发、生产及商业化。公司的主要产品是奥布替尼、坦昔妥单抗及mesutoclax。","listedPrice":11.03},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺诚健华(688428)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺诚健华(688428)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺诚健华,688428,诺诚健华股票,诺诚健华股票老虎,诺诚健华股票老虎国际,诺诚健华行情,诺诚健华股票行情,诺诚健华股价,诺诚健华股市,诺诚健华股票价格,诺诚健华股票交易,诺诚健华股票购买,诺诚健华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺诚健华(688428)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺诚健华(688428)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}